Tanshinone IIA inhibits epithelial-mesenchymal transition in ovarian cancer by promoting NR3C2 transcriptional activation of ING1
Xiaoqin Wang, Duoyi Zhang, Tingting Wang, Xin Li, Jing Zhang · 2026
Read Tanshinone IIA inhibits epithelial-mesenchymal transition in ovarian cancer by promoting NR3C2 transcriptional activation of ING1 by Xiaoqin Wang, Duoyi Zhang, Tingting Wang, Xin Li, Jing Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197640.txt.
Description
Xiaoqin Wang and co-authors test a plant compound against ovarian cancer in a 2026 lab study. Ovarian cancer is among the deadliest cancers of the female reproductive system. The compound, Tanshinone IIA, comes from a traditional medicinal herb. The team studied how it affects a process called EMT, in which cancer cells loosen and gain the ability to spread.
The compound slowed cancer cell growth, movement, and invasion, and it blocked the spread program in a dose based way. It worked by raising levels of a receptor protein, which switches on a growth blocking gene. When the receptor was knocked down, the compound lost much of its force. Turning the gene back on rescued the effect. Patient data backed the chain: low levels of both proteins tracked with advanced stage and worse survival.
Catalog record
| CREATOR | Xiaoqin Wang, Duoyi Zhang, Tingting Wang, Xin Li, Jing Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 77 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |